Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B167, Alone and in Combination With Tislelizumab in Chinese Patients With Selected Advanced or Metastatic Solid Tumors

This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BGB-B167 monotherapy and in combination with tislelizumab (BGB-A317) in participants with select advanced solid tumors in Chinese participants

Study Overview

• Status: Withdrawn
• Conditions: Solid Tumors
• Intervention / Treatment: Drug: BGB-B167; Drug: Tislelizumab

• Study Type: Interventional
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: BeiGene; Phone Number: 1-877-828-5568; Email: clinicaltrials@beigene.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participants with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors previously treated with standard systemic therapy or for whom treatment is not available, not tolerated, or refused, or not expected to provide significant clinical benefit or be tolerated in the medical judgement of the investigator
• Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1
• Adequate organ function as indicated by laboratory values during screening or ≤ 7 days before the first dose of study drug(s)
• Women of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study
• Nonsterile men must be willing to use highly effective method of birth control for the duration of the study

Exclusion Criteria:

• Active leptomeningeal disease or uncontrolled, untreated brain metastasis
• Active autoimmune diseases or history of autoimmune diseases that may relapse
• Any malignancy ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent
• History of severe hypersensitivity reactions to other monoclonal antibody products or their excipients
• Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers
• Known history of HIV infection.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Phase 1a: Dose Escalation; Part A: Increasing dose levels of BGB-B167 monotherapy; Part B: Increasing dose levels of BGB-B167 in combination with tislelizumab (BGB-A317)	Drug: BGB-B167; Intravenous administration; Drug: Tislelizumab; Intravenous administration; Other Names: BGB-A317
Experimental: Phase 1b: Dose Expansion; BGB-B167 alone or in combination with tislelizumab (BGB-A317)	Drug: BGB-B167; Intravenous administration; Drug: Tislelizumab; Intravenous administration; Other Names: BGB-A317

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)		Up to Approximately 30 months
Phase 1a: Number of Participants Experiencing AEs Meeting Protocol-defined Dose-limiting Toxicity (DLT) Criteria		Up to Approximately 24 months
Phase 1a: Maximum Tolerated Dose (MTD) of BGB-B167	The maximum tolerated dose (MTD) is defined as the highest tolerated dose for which the estimated toxicity rate is closest to the target toxicity rate of 30%.	Approximately 30 months
Phase 1a: Recommended Phase 2 doses (RP2Ds)	RP2Ds of BGB-B167 alone or in combination with tislelizumab will be determined based on a biologically effective dose	Approximately 24 months
Phase 1b: Objective Response Rate (ORR) as determined by investigators per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1	ORR is defined as the proportion of participants who had confirmed complete response (CR) or partial response (PR).	Up to Approximately 30 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase 1a: ORR	ORR is defined as the proportion of participants who had confirmed complete response (CR) or partial response (PR) as determined by investigators per RECIST v1.1.	Up to Approximately 30 months
Phase 1a and Phase 1b: Duration of Response (DOR) as determined by investigators per RECIST v1.1.	DOR is defined as the time from the first determination of a confirmed objective response until the first documentation of progression or death due to any cause, whichever occurs first.	Up to Approximately 30 months
Phase 1a and Phase 1b: Disease Control Rate (DCR) as determined by investigators per RECIST v1.1.	DCR is defined as the proportion of participants with best overall response (BOR) of confirmed CR, PR, or stable disease	Up to Approximately 30 months
Phase 1a and Phase 1b: Clinical Benefit Rate (CBR) as determined by investigators per RECIST v1.1.	CBR is defined as the proportion of participants with BOR of confirmed CR, PR, or stable disease lasting ≥ 24 weeks.	Up to Approximately 30 months
Phase 1b: Progression Free Survival (PFS) as determined by investigators per RECIST v1.1.	PFS is defined as the time from the date of the first administration of study drug to the date of the first documentation of disease progression or death due to any cause, whichever occurs first.	Up to Approximately 30 months
Phase 1a and Phase 1b: Maximum Serum Concentration (Cmax) of BGB-B167		Up to Approximately 30 months
Phase 1a and Phase 1b: Minimum Observed Plasma Concentration (Cmin) of BGB-B167		Up to Approximately 30 months
Phase 1a and Phase 1b: Time to Cmax (Tmax) of BGB-B167		Up to Approximately 30 months
Phase 1a: Terminal half-life (t1/2) of BGB-B167		Up to Approximately 30 months
Phase 1a: Area Under the Plasma Concentration-time curve (AUC0-7d) of BGB-B167		Up to Approximately 30 months
Phase 1a: Clearance (CL) BGB-B167		Up to Approximately 30 months
Phase 1a: Volume of Distribution at Steady State (Vss) of BGB-B167		Up to Approximately 30 months
Phase 1a and Phase 1b: Number of Participants with Anti-Drug Antibodies (ADAs)		Up to Approximately 30 months
Phase 1b: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)		Up to Approximately 30 months

Collaborators and Investigators

• Sponsor: BeiGene

Study record dates

Study Major Dates

• Study Start (Estimated): March 1, 2024
• Primary Completion (Estimated): March 1, 2025
• Study Completion (Estimated): August 1, 2025

Study Registration Dates

• First Submitted: December 1, 2022
• First Submitted That Met QC Criteria: December 1, 2022
• First Posted (Actual): December 9, 2022

Study Record Updates

• Last Update Posted (Actual): November 29, 2023
• Last Update Submitted That Met QC Criteria: November 27, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Antineoplastic Agents; Antineoplastic Agents, Immunological; Tislelizumab
• Other Study ID Numbers: BGB-A317-B167-102

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No